(Q40108015)

English

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Andrew H Ko

1

1 reference

Europe PubMed Central

17 September 2017

Elizabeth Dito

2

1 reference

Europe PubMed Central

17 September 2017

Brian Schillinger

3

1 reference

Europe PubMed Central

17 September 2017

Alan P Venook

4

1 reference

Europe PubMed Central

17 September 2017

Zhidong Xu

5

1 reference

Europe PubMed Central

17 September 2017

Emily K Bergsland

6

1 reference

Europe PubMed Central

17 September 2017

Derrick Wong

7

1 reference

Europe PubMed Central

17 September 2017

Janet Scott

8

1 reference

Europe PubMed Central

17 September 2017

Jimmy Hwang

9

1 reference

Europe PubMed Central

17 September 2017

Margaret A Tempero

10

1 reference

Europe PubMed Central

17 September 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

17 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

17 September 2017

26

1 reference

Europe PubMed Central

17 September 2017

463-471

1 reference

Europe PubMed Central

17 September 2017

5

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-008-9127-2

0 references

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-008-9127-2

21 January 2018

Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of angiogenesis in human pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-008-9127-2

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

release_7l26hn7j7ngmnbzpnswhprsc2a

1 reference

https://api.fatcat.wiki/v0/release/7l26hn7j7ngmnbzpnswhprsc2a

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40108015&oldid=1838136198"